Figure 4.

Targets and recommended treatment for the LDL-c control.

Adapted from the online cardiovascular risk stratification tool developed by the Brazilian Society of Cardiology, Department of Atherosclerosis, Brazilian Society of Endocrinology and Metabology and the Brazilian Society of Diabetes.²⁹

*Rosuvastatin and pravastatin are preferred treatments. Simvastatin and atorvastatin should be used with caution due to the possibility of drug interactions through the metabolism route.

^¥Expected % of reduction.

^†Target for LDL-c (mg/dL).

^‡Target for non-HDL-c (mg/dL).